ACAD250117P27000
- 12.00
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
ACADIA Pharmaceuticals (ACAD) Receives a Buy From RBC Capital
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $20
Analysts Conflicted on These Healthcare Names: Avadel Pharmaceuticals (AVDL) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings
Guggenheim Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Announces Target Price $20
Baird Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $28
JMP Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $39
JMP Securities Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $32
ACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy Rating
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $32
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $32
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $18 to $39
ACADIA Pharmaceuticals: Strong Buy Rating Backed by Promising Growth and Undervalued Assets
Stifel Nicolaus Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $20 to $39
ACADIA Pharmaceuticals Analyst Ratings
Buy Rating for ACADIA Pharmaceuticals Amid Strong Financial Performance and Growth Prospects
Guggenheim Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating